Published in Oncogene on October 19, 2015
Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. J Cancer Res Clin Oncol (2016) 0.76
A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts. Oncotarget (2016) 0.75
Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. Oncotarget (2016) 0.75
A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer. Oncol Lett (2017) 0.75
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol (1996) 4.25
Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol (2000) 4.19
Stromal biology and therapy in pancreatic cancer. Gut (2010) 3.80
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal Chem (1997) 3.09
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35
A novel putative receptor protein tyrosine kinase of the met family. Oncogene (1993) 2.06
Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science (1994) 1.84
A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol (1996) 1.65
Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene (2003) 1.59
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res (2006) 1.52
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res (2007) 1.47
Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene (2004) 1.43
Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res (2010) 1.31
Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer (2007) 1.26
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res (2004) 1.26
MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer (2013) 1.17
Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem (2009) 1.15
Interactions of the NPXY microdomains of the low density lipoprotein receptor-related protein 1. Proteomics (2009) 1.07
The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene (2008) 1.02
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes Cancer (2011) 1.01
Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov (2013) 1.00
Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer (2000) 1.00
Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev Immunol (2013) 1.00
Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem (2005) 0.99
The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem (2003) 0.97
RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem (2009) 0.93
Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. Cancer Res (2013) 0.92
The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells. Pancreas (2010) 0.89
RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Lett (2013) 0.88
Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase. Mol Cancer (2010) 0.87
Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther (2013) 0.84
RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer (2012) 0.83
Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor. Curr Cancer Drug Targets (2013) 0.82
Ron receptor tyrosine kinase signaling as a therapeutic target. Expert Opin Ther Targets (2012) 0.80
Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase. PLoS One (2012) 0.80
The ron receptor tyrosine kinase: a key regulator of inflammation and cancer progression. Crit Rev Immunol (2013) 0.78